X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS DR. REDDYS LAB DR. DATSONS LABS/
DR. REDDYS LAB
 
P/E (TTM) x -10.9 29.9 - View Chart
P/BV x 0.2 2.9 5.5% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 DR. DATSONS LABS   DR. REDDYS LAB
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
DR. REDDYS LAB
Mar-17
DR. DATSONS LABS/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1263,397 3.7%   
Low Rs312,560 1.2%   
Sales per share (Unadj.) Rs133.0856.5 15.5%  
Earnings per share (Unadj.) Rs0.278.0 0.2%  
Cash flow per share (Unadj.) Rs6.6139.9 4.7%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs128.8739.8 17.4%  
Shares outstanding (eoy) m31.66165.74 19.1%   
Bonus/Rights/Conversions FCCBBB-  
Price / Sales ratio x0.63.5 16.9%   
Avg P/E ratio x516.138.2 1,351.0%  
P/CF ratio (eoy) x11.821.3 55.6%  
Price / Book Value ratio x0.64.0 15.1%  
Dividend payout %025.7 0.0%   
Avg Mkt Cap Rs m2,477493,632 0.5%   
No. of employees `000NA22.7 0.0%   
Total wages/salary Rs m5631,068 0.2%   
Avg. sales/employee Rs ThNM6,259.0-  
Avg. wages/employee Rs ThNM1,369.8-  
Avg. net profit/employee Rs ThNM569.7-  
INCOME DATA
Net Sales Rs m4,211141,961 3.0%  
Other income Rs m791,715 4.6%   
Total revenues Rs m4,289143,676 3.0%   
Gross profit Rs m56924,722 2.3%  
Depreciation Rs m20410,266 2.0%   
Interest Rs m430634 67.9%   
Profit before tax Rs m1315,537 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2349 -0.5%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62,965 0.2%   
Profit after tax Rs m512,921 0.0%  
Gross profit margin %13.517.4 77.5%  
Effective tax rate %48.019.1 251.7%   
Net profit margin %0.19.1 1.3%  
BALANCE SHEET DATA
Current assets Rs m6,85296,837 7.1%   
Current liabilities Rs m6,71184,199 8.0%   
Net working cap to sales %3.38.9 37.6%  
Current ratio x1.01.2 88.8%  
Inventory Days Days16173 219.3%  
Debtors Days Days31898 326.1%  
Net fixed assets Rs m3,673102,552 3.6%   
Share capital Rs m317829 38.2%   
"Free" reserves Rs m3,761121,792 3.1%   
Net worth Rs m4,078122,621 3.3%   
Long term debt Rs m1,6715,449 30.7%   
Total assets Rs m12,633218,165 5.8%  
Interest coverage x1.025.5 4.0%   
Debt to equity ratio x0.40 922.1%  
Sales to assets ratio x0.30.7 51.2%   
Return on assets %3.46.2 55.4%  
Return on equity %0.110.5 1.1%  
Return on capital %7.712.9 59.5%  
Exports to sales %22.954.6 41.9%   
Imports to sales %14.39.4 152.9%   
Exports (fob) Rs m96477,520 1.2%   
Imports (cif) Rs m60213,274 4.5%   
Fx inflow Rs m96481,670 1.2%   
Fx outflow Rs m60726,355 2.3%   
Net fx Rs m35755,315 0.6%   
CASH FLOW
From Operations Rs m1,34521,444 6.3%  
From Investments Rs m-2,256-18,404 12.3%  
From Financial Activity Rs m-1,200-3,692 32.5%  
Net Cashflow Rs m-2,111-1,144 184.5%  

Share Holding

Indian Promoters % 4.5 25.5 17.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 5.4 -  
FIIs % 1.4 35.3 3.8%  
ADR/GDR % 0.0 18.5 -  
Free float % 94.1 15.3 615.0%  
Shareholders   20,807 75,885 27.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

Khadim India Ltd. (IPO)

Oct 31, 2017

Should you subscribe to the IPO of Khadim India Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS